Corona Remedies IPO Analyzed

The Corona Remedies Initial Public Offering (IPO) was incredibly successful. Investors showed strong interest, bidding for 62,65,41,440 shares compared to the company’s initial offering of just 45,71,882 shares. This means the IPO was subscribed 137.04 times – a fantastic sign of confidence in the company. Let’s break down the details to understand why this was such a successful offering.

Key Points

• Huge investor demand: Bids exceeded the initial share offering by 137.04x.
• Strong QIB interest: Qualified Institutional Buyers subscribed 278.52 times.
• Retail investors also keen: Retail investors subscribed 28.73 times.
• IPO raised Rs 655.37 crore: A complete sale of shares by existing owners.
• Promoters held 72.5% pre-IPO: The company’s founders controlled a large portion.
• Anchor investors secured Rs 194.85 crore: Pre-IPO investments boosted confidence.

The IPO ran from December 8th to December 10th, 2025, with a price range of Rs 1,008 to Rs 1,062 per share. The company aimed to raise around Rs 655.37 crore. Existing shareholders, including the company’s founders and investment trusts, were selling their shares.

Corona Remedies focuses on making and selling medicines for women’s health, heart and diabetes, pain relief, and treating urinary problems. They make most of their money from their women’s health and heart-related medicines – about 53% of their sales come from these areas.

As of June 30, 2025, they have 71 different medicines, covering all these health areas. Almost all of their sales – 96.34% – happen in India, with just a small amount of sales overseas (3.66%). They’re particularly strong in the western part of India, including states like Gujarat and Maharashtra.

Before the IPO, the company already secured Rs 194.85 crore from 17 investors who bought shares in advance. This pre-IPO funding helped show investors were interested and gave the company a good start.

For the three months ending September 30, 2025, Corona Remedies made a profit of Rs 46.20 crore and sold medicines for Rs 346.54 crore. These figures demonstrate the company’s growing success and market potential.

Investors’ enthusiasm created an IPO that significantly exceeded expectations, validating the company’s vision and strategy.